Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 70.75B 61.45B 57.07B 52.63B 99.14B 6,755B 101B 676B 265B 3,355B 266B 260B 11,281B P/E 2026 *
19.5x
P/E 2027 * 15.3x
Enterprise Value 62.93B 54.66B 50.76B 46.81B 88.18B 6,008B 89.77B 601B 235B 2,984B 236B 231B 10,034B EV / Sales 2026 *
3.85x
EV / Sales 2027 * 3.41x
Free-Float
72.33%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
1 day+6.17%
1 week+13.26%
Current month+18.41%
1 month+18.41%
3 months+4.42%
6 months-0.42%
Current year-4.34%
1 week 659.53
Extreme 659.53
740
1 month 625.7
Extreme 625.7
740
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-200 0.0002%
19/2/26 Fiscal year

Director

4,914 0.0048%
9/2/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+6.17%+13.26%+33.13%-1.04% 70.75B
-13.51%-10.70%+17.04%+172.20% 54.35B
+3.25%+52.70%+52.70%+52.70% 47.19B
-4.20%+5.94%-54.77%-54.33% 42.48B
-0.62%+3.64%+64.19%-21.60% 30.91B
-3.23%+5.40%+58.59%+94.94% 25.76B
+6.29%+1.58%+80.16%-51.19% 21.62B
+0.34%-3.08%-10.36%+155.06% 19.91B
-0.13%+2.03%+67.23%+129.42% 16.9B
-1.68%-0.95%+80.05%+138.64% 16.33B
Average -0.74%+2.90%+38.80%+61.48% 34.62B
Weighted average by Cap. -0.90%+3.87%+31.47%+51.05%

Financials

2026 *2027 *
Net sales 16.35B 14.2B 13.19B 12.16B 22.91B 1,561B 23.32B 156B 61.12B 775B 61.39B 60.04B 2,606B 17.66B 15.34B 14.25B 13.14B 24.75B 1,686B 25.2B 169B 66.04B 837B 66.33B 64.87B 2,816B
Net income 4.94B 4.29B 3.98B 3.67B 6.92B 471B 7.04B 47.15B 18.46B 234B 18.54B 18.14B 787B 5.18B 4.5B 4.18B 3.85B 7.26B 495B 7.39B 49.48B 19.37B 246B 19.46B 19.03B 826B
Net Debt -7.82B -6.79B -6.31B -5.82B -10.96B -747B -11.16B -74.7B -29.25B -371B -29.38B -28.73B -1,247B -10.51B -9.13B -8.48B -7.82B -14.73B -1,004B -15B -100B -39.31B -498B -39.48B -38.62B -1,676B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
30/07/26 USD 738.34 +6.17% 1,460,842
29/07/26 USD 695.42 +0.03% 1,022,421
28/07/26 USD 695.18 +4.20% 900,408
27/07/26 USD 667.17 +1.70% 650,984
24/07/26 USD 656.01 +0.63% 708,392
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
738.41USD
Average target price
815.37USD
Spread / Average Target
+10.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock